Brussels, Belgium
06.06.16 - 06.06.16
Take stock of where we stand in the EU on falsified medicines and paint the landscape of the global issue
Attend this essential conference to hear from key speakers who will present the approaches of the Member States on the implementation of the new legislation, and the impact and achievements of the concerned stakeholders such as industry, patients, pharmacies and distributors who have worked independently and together to find solutions.
Preliminary programme* includes
Key Note: How the Issue of Falsified Medicines has Evolved and what are the Global Implications?
Developments Within Europe and who are Affected
Session 1 – The views from the European Commission and Member States, including Belgium, Luxembourg, Spain and the UK. Topics include serialization, data protection, national reimbursement systems and IT systems or unique identifiers linked to those.
Session 2 Panel discussion with various stakeholders in the supply chain, including innovator industry, community and hospital pharmacists, generic and biosimilar industry and patients, to discuss the implementation on each part of the chain.
Speakers include
Attend this essential conference to hear from key speakers who will present the approaches of the Member States on the implementation of the new legislation, and the impact and achievements of the concerned stakeholders such as industry, patients, pharmacies and distributors who have worked independently and together to find solutions.
Preliminary programme* includes
Key Note: How the Issue of Falsified Medicines has Evolved and what are the Global Implications?
Developments Within Europe and who are Affected
Session 1 – The views from the European Commission and Member States, including Belgium, Luxembourg, Spain and the UK. Topics include serialization, data protection, national reimbursement systems and IT systems or unique identifiers linked to those.
Session 2 Panel discussion with various stakeholders in the supply chain, including innovator industry, community and hospital pharmacists, generic and biosimilar industry and patients, to discuss the implementation on each part of the chain.
Speakers include
- Hugo Bonar, Enforcement Manager, Health Products Regulatory Authority, Ireland
- Patrizia Tosetti, Policy Officer, European Commission
- Marcin Wisniewski, Pharmacy Inspector, Ministry of Health, Luxembourg
- Belén Escribano, Head of Department, Pharmaceutical Inspection and Enforcement Department, AEMPS, Spain
- Gerald Heddell, Director, Inspection Enforcement & Standards Division, MHRA, UK
- François-Xavier Lery, Head of Section for Pharmaceutical Care, Consumer Health Protection and Anti-Counterfeiting, European Directorate of Quality of Medicines & Healthcare, France
- Maarten Van Baelen, Director, Medicines for Europe, Belgium
- Tania Snioch, Director, Healthcare, GS1, Belgium